Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04440176 · ClinicalTrials.gov registry record · Phase 2
A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 309
- Enrollment target
NCT04440176 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 309 participants.
The verdict
NCT04440176, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 309 participants
- Enrollment target
Study Summary
This study is designed to describe the short-term immunogenicity and safety of 2 doses of Neisseria meningitidis group A, B, C, W, and Y vaccine (MenABCWY) separated by either 12 or 36 months during adolescence, and immunopersistence up to 24 months after completing 2 doses separated by a 12-month interval.
Interventions
- BIOLOGICAL Saline
- BIOLOGICAL MenABCWY
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 309 participants |
| Start Date | 2020-06-17 |
| Est. Completion | 2024-01-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04440176
The ClinicalTrials.gov registry entry for NCT04440176 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 309 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT04440176 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04440176 about?
NCT04440176 is a clinical study titled "A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules". This study is designed to describe the short-term immunogenicity and safety of 2 doses of Neisseria meningitidis group A, B, C, W, and Y vaccine (MenABCWY) separated by either 12 or 36 months during adolescence, and immunopersistence up to 24 months after completing 2 doses separated by a 12-month i...
What is the current status of trial NCT04440176?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 309 participants. The study started on 2020-06-17. Estimated completion is 2024-01-05.
What interventions are being tested in trial NCT04440176?
The interventions under investigation include: Saline (BIOLOGICAL), MenABCWY (BIOLOGICAL).
Who is sponsoring clinical trial NCT04440176?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.